Related Experiment Video
Updated: Jul 7, 2026
08:21
Effects of Blast-induced Neurotrauma on Pressurized Rodent Middle Cerebral Arteries
Published on: April 1, 2019
Beta-blockers in isolated blunt head injury
Kenji Inaba1, Pedro G R Teixeira, Jean-Stephane David
1Division of Trauma Surgery and Surgical Critical Care, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA.
Journal of the American College of Surgeons
|March 1, 2008
Summary
Beta-blocker use in patients with traumatic brain injury is linked to better survival rates. This effect was most pronounced in older patients with severe head injuries, showing a significant reduction in mortality.
Area of Science:
- Neuroscience
- Pharmacology
- Trauma Surgery
Background:
- Traumatic brain injury (TBI) is a significant cause of mortality and morbidity.
- The role of beta-blockers in TBI management remains incompletely understood.
Purpose of the Study:
- To investigate the association between beta-blocker administration and survival outcomes in patients with acute traumatic brain injury.
- To determine if beta-blocker exposure influences in-hospital mortality following isolated head injury.
Main Methods:
- Retrospective analysis of trauma registry and ICU databases from an academic Level I trauma center (July 1998 - December 2005).
- Inclusion criteria: patients with isolated blunt head injury requiring ICU admission.
- Exclusion criteria: patients with major associated injuries (Abbreviated Injury Score > or = 4 in other body regions).
- Data abstracted included demographics, injury characteristics, Injury Severity Score, and beta-blocker exposure.
- Primary outcome: in-hospital mortality.
Main Results:
- 1,156 patients with isolated head injury were analyzed; 203 (18%) received beta-blockers.
- Beta-blocker recipients were older and had more severe head injuries.
- Beta-blocker use was independently associated with reduced in-hospital mortality (adjusted odds ratio: 0.54; 95% CI, 0.33 to 0.91; p = 0.01).
- In subgroup analysis, elderly patients (>=55 years) with severe head injury showed a marked mortality reduction with beta-blockers (28% vs. 60%; odds ratio: 0.3).
Conclusions:
- Beta-blockade is independently associated with improved survival in patients with traumatic brain injury.
- The most significant survival benefit of beta-blockers was observed in older patients with severe head injuries.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Traumatic Brain Injury l: Introduction
DefinitionTraumatic brain injury, or TBI, is a disturbance of normal brain function induced by an external mechanical force, such as a direct blow to the head or a penetrating injury. It can affect both brain structure and function, producing a wide range of clinical outcomes. TBI is a heterogeneous condition, meaning its effects may differ based on the type, location, and severity of the injury.Basis of ClassificationTBI is classified based on severity, injury mechanism, or pathophysiology. In...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...